Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.
Myasthenia gravis is an autoimmune disorder that affects the neuromuscular junction; it cannot be entirely prevented. However, patients do often have symptoms in common that appear frequently before diagnosis. In part 2 of this interview with The American Journal of Managed Care®, Richard J. Nowak, MD, MS, associate professor of neurology; director, myasthenia gravis clinic; and director, program for clinical and translational neuromuscular research, Yale School of Medicine, explains some of these early myasthenia gravis symptoms and their impact on research efforts.
Revisit part 1 of this interview, where Nowak discusses late-breaking data from the MINT trial (NCT04524273), investigating inebilizumab, that he presented at the 2025 American Academy of Neurology annual meeting.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
Are there early in-common symptoms among patients who have myasthenia gravis?
Myasthenia gravis is an autoimmune condition that affects neuromuscular transmission. The clinical symptoms that we see are fatigable muscle weakness. Most commonly, in fact, in up to 90% of individuals, the first presenting symptom is an ocular symptom—double vision or eyelid droop or combination of both—we observe that in the majority of patients, regardless of the antibody subtype that they might have. Patients in about 50% to 75% of cases will progress to a generalized form of myasthenia gravis. This can include things like difficulty speaking, so slurred speech; fatigue with chewing; choking on food; and also weakness in their arms and legs are not uncommon symptoms that we observe.
How can identifying these early symptoms help guide future research efforts?
I think early recognition and early diagnosis is something that we do need to pay attention to. It has been observed over the years that there can be a delay to diagnosis of up to 2 or so years from the initial symptom, looking retrospectively back. I think that's certainly much more common in individuals that present with milder symptoms or subtle symptoms, where the symptoms might fluctuate—so by the time they might reach their physician, primary care, or ophthalmologist, for instance, in the case of double vision, the symptoms and exam findings might have completely resolved, so an evaluation might not necessarily be pursued. Myasthenia gravis, as a rare condition, is not the first thing that comes to mind when someone might have double vision or eyelid droop, per se, but it certainly should be on the radar of physicians in primary care, ophthalmology, or in neurology for sure.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Workers Facing Greater Economic Hardship More Likely to Report Poor Health
June 2nd 2025US workers facing high economic hardship, especially those in lower-wage occupations, were significantly more likely to report fair or poor health, underscoring persistent disparities in worker well-being.
Read More
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More